Aldevron licenses HyperGRO™ DNA manufacturing technology from Nature Technology Corporation.
Fargo, ND (July 27, 2010) Aldevron, a biotechnology company, has licensed the HyperGRO™ DNA production processes from Nature Technology Corporation (NTC) for use in Aldevron’s clinical manufacturing programs.
According to Michael Chambers, President and CEO of Aldevron, “We are very excited to have access to Nature’s HyperGRO™ technology. By working together, Aldevron and NTC can provide our clients’ with better options for clinical-grade manufacturing.“ NTC’s HyperGRO™ processes will be combined with Aldevron’s downstream purification technology to manufacture DNA vaccine and gene therapy products. The result will be a very high-yielding DNA production process that will allow Aldevron to manufacture larger amounts of DNA for an increased number of applications.
After collaborating with NTC for several years, our testing and evaluation indicates that NTC’s HyperGRO™ plasmid purification processes provide some of the best yields and highest purity for many applications while also maintaining the fidelity and integrity of the plasmid. This will address client requirements for dramatically increased product yield and purity at a very competitive cost.
By combining Aldevron’s advances in biologics manufacturing and purification with NTC’s HyperGRO™ processes, Aldevron continues to lead the industry as the vendor of choice for custom plasmid manufacture and high quality service.
Company Information:
Aldevron is the leading provider of plasmid DNA for use in research, diagnostic and clinical applications. Aldevron provides services to many biopharmaceutical companies, life science tools & technology companies, as well as government and academic research groups. The company has developed quality systems and novel technology that allows for more cost-effective production of biological molecules that are used globally in preclinical and clinical research.
Nature Technology Corporation (NTC) is a technology-based biologics development company, providing vector design and construction, process development and manufacturing (OEM) assistance to biotech and bio-pharmaceutical companies. NTC’s mission is to provide essential platform technology and services for the construction, delivery, and expression of new age biologics, including DNA vaccines, gene therapeutics, and recombinant proteins. The company is located in The University of Nebraska Technology Park in Lincoln, Nebraska.
